Business Wire

ADVA

11.11.2021 09:02:09 CET | Business Wire | Press release

Share
ADVA launches new traffic grooming solution to reduce metro costs

ADVA (FSE: ADV) today launched its FSP 3000 OpenFabric1200™ solution to help network operators significantly reduce metro costs. The OTN-based technology enables client services to be groomed into 400Gbit/s wavelengths, maximizing fiber capacity and supporting cost-efficient coherent networks. The latest member of the FSP 3000 OpenFabric Series combines open 400Gbit/s pluggable coherent technology with OTN switching on a blade, increasing wavelength efficiency. The open switchponder card can be added to any network without requiring additional adaptors. Specifically engineered for the 400Gbit/s era, the ADVA FSP 3000 OpenFabric1200 features 1200Gbit/s interface capacity and supports Ethernet and OTN services from 10Gbit/s to 400Gbit/s.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005220/en/

“The strain on today’s transport infrastructure is growing like never before. Today’s operators need new solutions that can meet rapidly rising data demand while also driving down costs. That’s why we’ve developed our FSP 3000 OpenFabric1200 . It offers a simple way to dramatically increase fiber efficiency by supporting lower-speed service grooming at the network edge. By deploying OpenFabric1200 in ring or hub-and-spoke topologies, operators can significantly reduce switching and cross-connect requirements in the core,” said Christoph Glingener, CTO, ADVA. “What’s more, our open Terabit-scale switchponder solution can be easily added to any network.”

The new technology is part of the ADVA FSP 3000 OpenFabric Series, a family of switchponders built for maximum openness, flexibility and scale. The OpenFabric1200 offers OTN switching with the benefits of open CFP2 pluggable coherent interfaces. With Terabit capacity, the new card is the ideal tool for leveraging more value from deployed metro infrastructure and upgrading legacy networks to the latest coherent pluggable technology. The FSP 3000 OpenFabric1200 can work in multiple operation modes: ADM on a blade, DWDM muxponders, or OTN cross-connect. What’s more, thanks to its open design, client services can be connected directly or via standard OTN-based transponders without the need for any adapters.

“Our FSP 3000 OpenFabric1200 will be a key tool in tackling skyrocketing bandwidth demand while supporting existing low-speed services. The technology takes our OpenFabric concept to the next level, enabling traffic grooming at the edge where it’s most efficient and delivering 1.2Tbit/s interface capacity. It offers the power to adapt to changing traffic demands without a hardware upgrade while simplifying operations and enabling network operators to scale as and when needed,” commented Cornelius Fürst, director, product line management, ADVA. “Our FSP 3000 OpenFabric1200 is the flexible OTN solution that’s about to switch things up. For metro network operators, our new switchponder opens the door to the benefits of disaggregated environments and the latest pluggable coherent 400Gbit/s technology.”

Watch this video for more information on the FSP 3000 OpenFabric1200™: https://youtu.be/ti101PI1fxw .

Further details are also available in these slides: https://adva.li/fsp-3000-openfabric1200-slides .

A supporting solution brief can be downloaded here: https://adva.li/fsp-3000-openfabric-series-solution-brief .


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye